Innoviva Inc  

(Public, NASDAQ:INVA)   Watch this stock  
Find more results for NASDAQ:THRX
12.60
+0.02 (0.16%)
Real-time:   2:25PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 12.44 - 12.99
52 week 8.67 - 14.55
Open 12.53
Vol / Avg. 942,903.00/1.15M
Mkt cap 1.38B
P/E 17.60
Div/yield     -
EPS 0.72
Shares 109.36M
Beta 2.57
Inst. own 72%
Oct 25, 2017
Q3 2017 Innoviva Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Sep 7, 2017
Innoviva Inc at Robert W Baird Gobal Healthcare Conference - 12:50PM EDT - Add to calendar
Jul 26, 2017
Q2 2017 Innoviva Inc Earnings Call - Webcast
Jul 26, 2017
Q2 2017 Innoviva Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin 60.02% 44.57%
Operating margin 81.67% 81.60%
EBITD margin - 92.04%
Return on average assets 36.91% 15.11%
Return on average equity - -
Employees 13 -
CDP Score - -

Address

2000 Sierra Point Pkwy Ste 500
BRISBANE, CA 94005-1830
United States - Map
+1-650-2389600 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Innoviva, Inc., formerly Theravance, Inc., is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement and the Strategic Alliance Agreement with GSK, the Company is eligible to receive the annual royalties from GSK on sales of RELVAR/BREO ELLIPTA. For other products combined with a LABA from the LABA collaboration, such as ANORO ELLIPTA, royalties are upward tiering and range from 6.5% to 10%. RELVAR/BREO is a once-a-day combination inhaled respiratory medicine consisting of a LABA (VI) and an inhaled corticosteroid (ICS), FF. ANORO ELLIPTA a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA.

Officers and directors

William H. Waltrip Independent Chairman of the Board
Age: 78
Bio & Compensation  - Reuters
Eric D'Esparbes Chief Financial Officer, Senior Vice President
Age: 49
Bio & Compensation  - Reuters
Theodore J. Witek Jr. Senior Vice President, Chief Scientific Officer
Age: 59
Bio & Compensation  - Reuters
Michael E. Faerm Senior Vice President and Chief Business Officer
Age: 50
Bio & Compensation  - Reuters
Michael W. Aguiar President, Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Barbara G. Duncan Independent Director
Bio & Compensation  - Reuters
Catherine J. Friedman Independent Director
Age: 56
Bio & Compensation  - Reuters
Patrick G. LePore Independent Director
Age: 62
Bio & Compensation  - Reuters
Paul A. Pepe Independent Director
Age: 57
Bio & Compensation  - Reuters